Key points are not available for this paper at this time.
Although no statistically significant OS benefit was observed, the HR numerically favored olaparib, which also conferred clinically meaningful benefits including increased time off chemotherapy and long-term survival in a subset of patients.
Kindler et al. (Thu,) studied this question.